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Elevated plasma EPO levels are related to the severity of CHF and are associated with
an impaired prognosis independent of hemoglobin levels and other established markers
of CHF severity. Furthermore, EPO levels poorly correlate with the Hb levels, in contrast
to the control group. The observed blunted EPO response to anemia in CHF needs fur-
ther study. 
1145-122 Prevention of Atrial Fibrillation in Symptomatic Chronic 
Heart Failure by Candesartan: Results From CHARM
Karl Swedberg, Marc Pfeffer, Alain Cohen-Solal, Anique Ducharme, Christopher 
Granger, Eric Michelson, John McMurray, James Young, Salim Yusuf, Sahlgrenska 
University Hospital/Östra, Göteborg, Sweden, Brigham & Women's Hospital, Boston, MA
Background: Atrial fibrillation (AF) is claimed to be associated with increased risk in
chronic heart failure (CHF). Small studies have suggested an effect of angiotensin-1
receptor blockers (ARB) on the incidence of AF. In the 3 CHARM (Candesartan in Heart
failure Assessment of Reduction in Mortality and morbidity trial) trials the effect of the
ARB, candesartan, was evaluated on cardiovascular mortality and morbidity in a broad
spectrum of patients with symptomatic CHF. We have assessed the impact of cande-
sartan compared with placebo on development of AF in CHARM.
Methods: In CHARM Overall 7601 patients with symptomatic CHF were randomized to
candesartan (target dose 32 mg, mean dose 24 mg) or placebo (including n=4576 with
LVEF<40% and n=3025 with LVEF>40%). Major exclusions included S-creatinine > 265
umol/l, S-potassium>5.5 mmol/l and symptomatic hypotension. Major outcomes
included: all-cause mortality, CV mortality and CV death or CHF hospitalizations. Mean
follow-up was 38 months. A prespecified Cox regression adjustment was performed
using baseline covariate variables. These variables included almost all baseline demo-
graphics collected.
Results: 5518 (72.6 %) pat. did not have AF at baseline. In the candesartan group, inci-
dence of new AF was 179 pat. (6.5%) compared to 216 pat. (7.9%) in the placebo group
(Odds ratio, OR= 0.82 (95% CI 0.67-1.00; p=0.054). After adjustment for the pre-speci-
fied baseline co-variates OR=0.81 (95% CI 0.66-1.00; p=0.048). There was no heteroge-
neity between the three component trials (p=0.50).
Conclusions: The ARB, candesartan, can prevent the development of AF in symptomatic
CHF.
1145-123 Inadequate Perception of Heart Failure Is Associated 
With Underuse of Diagnostic and Therapeutic 
Strategies in Heart Failure by the Primary Care 
Physician: Results From SHAPE, a Major European 
Survey
Willem J. Remme, Charles Cline, Alain Cohen Solal, Rainer Dietz, Richard Hobbs, Karen 
Keukelaar, Jose Lopez Sendon, Cezar Macarie, John McMurray, Christina Opasich, 
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Background: Novel diagnostic and therapeutic strategies in heart failure (HF) signifi-
cantly improve prognosis and attenuate disease progression, thereby reducing morbidity.
In Europe, the majority of HF patients are cared for by primary care physicians (PCPs). It
is unknown to what extent European PCPs perceive these new developments and apply
them to clinical practice.
Methods: SHAPE (Study of Heart failure Awareness and Perception in Europe)
assessed awareness and perception of HF in 3000 randomly selected PCPs in France,
Germany, Italy, Netherlands, Poland, Romania, Spain, Sweden and UK. Native language
questionnaires were used, consisting of 31 questions covering epidemiology, aetiology
and diagnostic and therapeutic strategies in HF.
Results: HF prevalence was clearly underestimated, 82% of PCPs thought it 1% or less.
PCPs would diagnose HF based on signs and symptoms alone in 75% of cases, and
22% believed the response to diuretics necessary to confirm the diagnosis. Although
more than 90% would regularly prescribe an ACE inhibitor (ACEi) plus diuretic, 39%
would always start treatment with a diuretic. When a patient would remain symptomatic
despite optimal ACEi and a diuretic, only 34% would add a beta-blocker. More would pre-
scribe digoxin or spironolactone. Target doses of ACEi and beta-blockade as indicated in
HF treatment guidelines would only be reached by 18-30% and 7-29% of PCPs, resp.
Beta-blockade was considered of high risk for worsening HF (38%), hypotension (34%),
heart block (61%) and bronchospasm (71%), and a reason to stop treatment. ACEi was
believed to lead to renal impairment (88%) and hypotension (94%), reasons to stop treat-
ment, but also to worsening HF by 35%. In contrast, 1/3 of PCPs did not consider angio-
edema a potential risk. As regards the benefit of new HF treatment, 69% voted for
improved quality of life, rather than survival. Finally, 68% incorrectly estimated the per-
centage of overall health care costs for HF as high as 5 - 25%.
Conclusion: The European PCPs perception of all aspects of HF is clearly inadequate.
Under-use of guideline-recommended diagnostic and therapeutic strategies indicates the
need for education of these essential health care providers.
1145-124 Trends and Outcomes in Long-Term Use of 
Anticoagulants on Congestive Heart Failure Patients: 
1999-2002
Allan Anderson, Phillip Brown, Aaron Kugelmass, Lynn Tarkington, Salvatore Battaglia, 
April Simon, Steven Culler, Edmund Becker, Emory University, Atlanta, GA, HCA, Inc., 
Nashville, TN
Background: CHF is an increasing patient population in the United States. Thrombo-
genic events which occur in the presence of CHF can be devastating. Long-term use of
anticoagulants in CHF patients has been shown to decrease thrmobotic events.
Methods: All patients with a primary diagnosis of CHF (DRG 127) from the HCA
Casemix Database; a dataset of all consecutive patients discharged from 191 HCA hos-
pitals treating CHF over the period January 1999 through December 2002. A total of
156,564 CHF admissions were analyzed. Co-morbid conditions, procedures, complica-
tions, and outcome variables were defined through ICD-9 coding. Odds ratios for five in-
hospital outcomes: death, ARF, cardiac complications, neurological complication, and
discharge home were estimated using logistic regression adjusting for age, gender, and
17 other patient co-morbid and procedural characteristics.
Results: Over 4 years, the mean age for CHF patients declined from 76 to 73 years of
age with males representing between 45% and 46% of the CHF population. The long-
term use of anticoagulation grew 56% over the 4-year period from 3.2% to 5.4% in
patients hospitalized with a primary diagnosis of CHF. Logistic regression demonstrated
that CHF patients on long-term anti-coagulation have lower mortality - 42% (p<0.001),
lower rates of ARF - 36% (p<0.001), and are more likely to be discharged home 37%
(p<0.001) than those not on long-term anticoagulation.
Conclusions: Long-term anticoagulation use in community based CHF management
has increased significantly (56%) from 1999-2002. Long-term use of anticoagulation was
associated with a significant decrease in incidence of in-hospital mortality and ARF. Addi-
tionally, CHF patients who were anticoagulated are significantly more likely to be dis-
charged home.
1145-125 The Role of Sildenafil in Establishing Pulmonary 
Arterial Reactivity in Advanced Heart Failure
Jamshid Alaeddini, Patricia A. Uber, Robert L. Scott, Myung H. Park, Hector O. Ventura, 
Mandeep R. Mehra, Ochsner Clinic Foundation, New Orleans, LA
Background: In patients with advanced heart failure, it is essential to document revers-
ibility of pulmonary hypertension (PH ) as part of pre-operative evaluation for cardiac
transplantation as well as to ascertain pharmacological responsiveness. Sildenafil, a
specific phosphodiesterase-5 inhibitor, has been shown to decrease pulmonary vascular
resistance (PVR) and might serve as an important agent in evaluating heart failure
related secondary PH.
Methods: We evaluated twelve consecutive patients (7 men, age 50 ±14 years, 6 non-
ischemic cardiomyopathy, left ventricular ejection fraction 25±15%) with chronic heart
failure and PH. Patients received oral doses of sildenafil 25 mg – 50 mg (upto 3 doses 8
hours apart. Their baseline medications included milrinone (n=7), dobutamine (n=7), and
nitroprusside (n=1) Nesiritide (n=3). All patients had a pulmonary artery catheter for inva-
sive hemodynamic measurements and serial alterations in pulmonary artery pressures
were assessed
Result: Hemodynamic changes were seen within 2 hours after the first dose of oral
sildenafil. Within 2 hours after the first dose of oral sildenafil systolic pulmonary artery
pressure (PAP) declined from 71±20 to 53±26 mmHg, Diastolic PAP from 29±9 to19±9
mmHg, pulmonary artery mean pressure from 43±12 to 31±14 mmHg, pulmonary wedge
pressure from 25±7 to 18±6 mmHg, PVR from 302±115 to 193±81 dyne. s/cm5, and sys-
temic vascular resistance from 1457±856 to 1095±694 dyne . s/cm5 (p<0.05 for all). Car-
diac index increased from 2.4±0.9 to 2.8±1.0 L/m2 per minute (p<0.05). All patients but
one had a positive hemodynamic response to oral sildenafil (more than 20% reduction in
mean PAP or PVR). There was no clinically significant drop in the blood pressure (pre-
sildenafil: systolic 109±20; diastolic 62±11 vs 106±22; 59±10 mmHg after drug adminis-
tration, p=NS). Patients did not experience any adverse effect associated with adminis-
tration of sildenafil.
Conclusion: Oral sildenafil appears to be an effective and safe agent for evaluation of
reactivity of PH. The pulmonary antihypertensive effects demonstrate selectivity for the
pulmonary vasculature with maintenance of systemic blood pressure.
